TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Aquestive Therapeutics ( (AQST) ) has shared an announcement.
Aquestive Therapeutics announced plans for the advancement of its product candidate Anaphylm, a sublingual film for epinephrine administration, through clinical development and potential FDA approval. The company is also progressing with its Adrenaverse pipeline, including AQST-108 for alopecia areata, and preparing for the commercial launch of Libervant, highlighting potential market growth and revenue opportunities.
The most recent analyst rating on (AQST) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Spark’s Take on AQST Stock
According to Spark, TipRanks’ AI Analyst, AQST is a Neutral.
Aquestive Therapeutics’ stock score is primarily impacted by its weak financial performance, characterized by declining revenues and high leverage. While technical analysis shows positive momentum, the valuation remains unattractive due to negative earnings. The earnings call provided some optimism regarding product development, but financial challenges persist.
To see Spark’s full report on AQST stock, click here.
More about Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing innovative medicines. The company specializes in sublingual film-based drug delivery systems and targets unmet medical needs in various therapeutic areas.
Average Trading Volume: 2,243,796
Technical Sentiment Signal: Buy
Current Market Cap: $683.5M
See more data about AQST stock on TipRanks’ Stock Analysis page.